Allergy Therapeutics plc (LON:AGY) insider Peter Jensen acquired 30,000 shares of the business’s stock in a transaction on Thursday, September 29th. The shares were purchased at an average price of GBX 19 ($0.25) per share, with a total value of £5,700 ($7,440.28).
Allergy Therapeutics plc (LON:AGY) opened at 19.50 on Tuesday. The firm’s market capitalization is GBX 114.89 million. The stock’s 50 day moving average is GBX 18.73 and its 200-day moving average is GBX 22.28. Allergy Therapeutics plc has a 1-year low of GBX 17.25 and a 1-year high of GBX 34.82.
AGY has been the subject of a number of analyst reports. Numis Securities Ltd restated a “buy” rating and set a GBX 37 ($0.48) price objective on shares of Allergy Therapeutics plc in a research report on Tuesday, September 27th. Panmure Gordon restated a “buy” rating and set a GBX 53 ($0.69) price objective on shares of Allergy Therapeutics plc in a research report on Monday, September 26th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 72 ($0.94) price objective on shares of Allergy Therapeutics plc in a research report on Friday, July 8th.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.